title-engageo.png
About Us

What is ENGAGe?

  • Established in 2012, the European Network of Gynaecological Cancer Advocacy Groups is a network of European patient advocacy groups established by ESGO representing all gynaecological cancers particularly (ovary, endometrial, cervix, vulva and rare cancers).

Why is ENGAGe needed?

  • There are wide variations in patient care across Europe
  • Patients are not adequately informed about gynaecological cancer and their management
  • Survivorship issues are not adequately addressed and psychosocial support in general is poor

The ENGAGe objectives are to:

  • Facilitate the development of national gynaecological cancer patient groups in Europe and to facilitate networking and collaboration between them.
  • Disseminate information and share best practices to empower patient groups and improve the quality of care across Europe.
  • To increase patient representation in ESGO activities by education on current research and health policy.
  • To advocate patient care policies practices and access to appropriate care at both national and European levels.
  • To educate patient groups, health professionals, the public and health decision makers.

Partners

  • Health Practitioners
  • Women's health networks
  • Patient Groups
  • Cancer Organisations

Key trends

  • multidisciplinary input to treatment plans
  • centralisation of specialist care
  • individualization of treatment
  • community care in local environment
  • survivorship (>1 year)

Active areas of research

  • Early diagnosis – primary care/community
  • Targeted therapy
  • Familial risk
  • Selection of subgroups likely to benefit from individualized treatment
  • Quality of Life

Why ESGO is the natural partner of patient networks

  • The size of membership and meeting attendance reflect its global influence to ensure the gynaecological cancer patient perspective becomes integrated in the European cancer voice.
  • Raise attention to the need for further research and improve access to quality treatment and care.
  • No vested interests other than patient health makes it ideally placed to influence governments.
  • Provides a comprehensive approach to the health of women with gynaecological cancer.
  • Prospect of private/public partnership funding e.g. FP7, Horizon 2020.